Doximity

Doximity

DOCS
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

DOCS · Stock Price

USD 26.03-33.16 (-56.02%)
Market Cap: $4.7B

Historical price data

Overview

Doximity's mission is to connect the healthcare ecosystem and make clinicians more productive through its dedicated digital platform. It has achieved dominant market penetration with over two million verified members, including the vast majority of U.S. physicians, creating a powerful network effect. The company's strategy centers on deepening engagement within its core network by expanding its integrated suite of workflow tools, thereby increasing its utility and monetization opportunities across pharmaceutical marketing, hospital recruitment, and telehealth services.

Digital HealthHealthcare IT

Technology Platform

A verified professional network and integrated software suite for U.S. healthcare clinicians, featuring telehealth, secure communication, clinical reference, and workflow tools, all built on a HIPAA-compliant architecture.

Opportunities

Doximity can deepen revenue by increasing product adoption and average revenue per user within its massive, captive network.
Expansion opportunities include further integration with EHRs, developing advanced data analytics products for enterprise clients, and potentially moving into adjacent services like credentialing or continuing medical education.

Risk Factors

Key risks include reliance on pharmaceutical marketing spend (cyclical), potential competition from EHR vendors or large tech companies, regulatory changes in telehealth or data privacy, and the need to continuously innovate to maintain high user engagement.

Competitive Landscape

Doximity faces fragmented competition across its product segments: LinkedIn for networking, Teladoc/Amwell for telehealth, and Veeva for pharma marketing. Its defensible moat is its scaled, verified clinician network and integrated workflow suite, which create powerful switching costs and network effects that are difficult to replicate.